RT Journal Article
T1 Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
A1 Gutiérrez-Saborido, D.
A1 Gutiérrez-Valencia, A.
A1 González-Doménech, Carmen María
A1 López Ruz, Miguel Ángel
A1 Raffo Márquez, Miguel
A1 Omar, Mohamed
A1 Girón-González, José Antonio
A1 Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI), 
K1 Linfomas
K1 SIDA Usado p
K1 Virus de la hepatitis C
AB The change in the incidence of lymphomas in function of the presence or absence of sustained virological response after anti-hepatitis C therapy in a cohort of human immunodeficiency (HIV)-hepatitis C (HCV) viruses coinfected patients was analyzed. A prospective cohort of 755 HIV-HCV coinfected patients who received their first anti-HCV therapy, based on interferon + ribavirin schemas, was evaluated. Incidence and histologic types of lymphomas were analyzed in two periods: (1) before administration of anti-HCV therapy and (2) after anti-HCV therapy. The association between lymphoma incidence and demographic, HIV- (minimum CD4+ cell count and CD4+ cell count at diagnosis of lymphoma, antiretroviral therapy, maximal HIV load and HIV load at diagnosis of lymphoma) and HCV-related variables (HCV load, genotype, sustained viral response to anti-HCV therapy) were analyzed. A total of 13 lymphomas [incidence rate (95% confidence interval), 0.72 (0.33-1.11) × 1000 person-years, time from HIV diagnosis to lymphoma diagnosis (median, interquartile range), 15 (11-19) years] were diagnosed. Nine of them were non-Hodgkin and four Hodgkin lymphomas. The median CD4+ T cell count at diagnosis of lymphoma was 457/mm3, with only two cases with values lower than 200/mm3. The incidence rate of non-Hodgkin lymphomas was similar pre- and post-anti HCV therapy [0.33 (0.00-0.65) vs 0.68 (0.08-1.26) × 1000 person-years, respectively, p > 0.05]. Patients with sustained virologic HCV response showed similar incidence rate of lymphomas than that of those without anti-HCV response. In conclusion, anti-HCV therapy does not modify the incidence rate of lymphomas in HIV-HCV coinfected patients.
PB Springer
YR 2019
FD 2019-04-25
LK https://hdl.handle.net/10630/29110
UL https://hdl.handle.net/10630/29110
LA eng
NO Gutiérrez-Saborido D, Gutiérrez-Valencia A, González Domenech CM, López Ruz MÁ, Raffo Márquez M, Omar M, Girón-González JA; Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy. Ann Hematol. 2019 Aug;98(8):1953-1959. doi: 10.1007/s00277-019-03700-3.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026